



ASX Announcement

29 May 2018

IDT RECEIVES FDA WARNING LETTER

IDT Australia Limited (IDT) provides the following market update:

IDT has received a Warning Letter from the U.S. Food and Drug Administration (FDA) in relation to a scheduled audit of its facilities which occurred in December 2017.

The warning letter highlighted concerns regarding the following processes in IDT's business:

1. Investigations of out of specification results and deviations; and the timely implementation of appropriate corrective actions; and
2. The ability of IDT's quality system to ensure integrity of data to support manufacture of its products.

IDT's new management team is taking this warning letter very seriously. Changes have already been made which include the recruitment of quality and operational personnel and remediation activities currently underway are directed at fully addressing the concerns expressed by the FDA. IDT is acting on this letter with the utmost priority, whilst fulfilling our current and future obligations to our customers.

ENDS

For further information please contact:
IDT Australia Limited
Dr David Sparling – Chief Executive Officer
0417 721 972